Detailed performance report for WATERS CORPORATION covering Q2 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Waters reported an excellent Q2 2026, with total revenue of $1.645B, including $828M of organic revenue and $817M from the acquired Biosciences and Diagnostic Solutions businesses. Organic revenue rose 7% reported / 9% constant currency, ahead of guidance, driven by strength across all divisions. Adjusted EPS was $3.05, up 3% and at the high end of guidance. Adjusted gross margin was 54% and adjusted operating margin was 25%. Free cash flow was $202M.
Company Outlook & Strategy: Management raised full-year 2026 guidance across revenue and earnings. Organic constant-currency revenue growth is now expected at 7%–9%, total revenue at $6.415B–$6.476B, and adjusted EPS at $14.45–$14.65, implying 10%–12% growth. The company expects $75M of 2026 cost savings and about $200M of run-rate savings, supporting margin expansion and mid-teens EPS growth over time. Waters remains focused on cross-selling, revenue synergies, pricing discipline, instrument replacement, and expanding into higher-growth adjacencies.
Key Industry Trends: End markets strengthened broadly, with double-digit pharma growth, improved U.S. biotech/CRO demand, and a recovery in China pharma and research activity. Academic/government also improved, while industrial remains mixed but supported by PFAS testing. Waters highlighted a multi-year pharma reshoring opportunity tied to U.S. pharma CapEx and continued demand recovery in instruments, though replacement cycles remain elongated versus history.
Operational Highlights: Legacy Waters delivered strong growth across Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Science. New product launches were a major theme, including Cyclic IMS P20, Xevo MRT P10, BioResolve Peptide and GTxResolve Lipid columns, Xevo TQ Absolute XR IVD, FACSDiscover A7, and BACTEC FXI. Management emphasized rapid execution under the 180-day plan, improved pricing realization, enhanced commercial discipline, China localization efforts, cost restructuring, and early benefits from cross-selling and service attachment.
Challenges & Risks: Key headwinds included foreign exchange, China-related pressure in Biosciences and Diagnostics, and ongoing DRG constraints in China. Management also noted potential softness in chemical analysis ordering patterns, tariff-related noise, and the still-extended instrument replacement cycle. Integration and remediation work remains underway, including compliance reviews on reagent rental contracts and execution risk around localization and launch timing.
Key Analyst Questions & Responses: Analysts asked whether BD Life Sciences can sustain above-5% growth and potentially become a 6%+ asset; management replied that execution has exceeded expectations and said the businesses should exit 2026 at 6% or better growth, helped by pricing, replacement cycles, localized products, and new launches. On pricing, management said acquired-business pricing realization was 0.9% in Q2 versus a prior 0.5% assumption, with the plan to reach 150 bps over time. Questions on EPS guidance were answered with the explanation that stronger revenue and cost actions were largely offset by FX. Tariff refund effects were described as net neutral.
Access the official earnings call transcript for WATERS-CORPORATION 2026 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.